Bacteroides fragilis Protects Against Antibiotic-Associated Diarrhea in Rats by Modulating Intestinal Defenses.
Bacteroides fragilis Protects Against Antibiotic-Associated Diarrhea in Rats by Modulating Intestinal Defenses.
复制标题
脆弱拟杆菌通过调节肠道防御来预防大鼠抗生素相关腹泻。
DOI：
10.3389/fimmu.2018.01040
复制
发表时间：
2018
影响因子：
7.3
通讯作者：
Zhi F
中科院分区：
文献类型：
--
作者：
Zhang W;Zhu B;Xu J;Liu Y;Qiu E;Li Z;Li Z;He Y;Zhou H;Bai Y;Zhi F
抗生素相关性腹泻（AAD）是以肠道微生物群破坏为特征的医源性腹泻。在临床实践中，益生菌通常用于治疗AAD;然而，益生菌缓解症状的有效性和机制仍然知之甚少。我们先前分离到一种无毒的脆弱拟杆菌菌株ZY-312，其已被证实对某些感染性疾病有益。然而，这种细菌在AAD中的确切作用尚不清楚。本研究通过对大鼠进行适当的抗生素暴露，成功地建立了AAD大鼠模型。这些大鼠出现腹泻症状，并显示出肠道微生物群的改变，包括一些致病菌的过度生长。此外，与对照动物相比，ADD大鼠中还检测到胃肠道屏障缺陷，表现为水通道蛋白表达受损、紧密连接蛋白异常和充满粘液的杯状细胞丰度降低。值得注意的是，口服B。fragilis菌株ZY-312通过增加特定肠道微生物群的丰度来改善AAD相关的腹泻症状。有趣的是，我们发现这些变化与AAD大鼠肠屏障功能和肠上皮细胞再生的恢复一致。总之，我们确定了一种潜在的益生菌治疗AAD的策略，并确定了B的重要作用。fragilis菌株ZY-312在调节结肠细菌群落和参与微生物群介导的上皮细胞增殖和分化中的作用。
Antibiotic-associated diarrhea (AAD) is iatrogenic diarrhea characterized by disruption of the gut microbiota. Probiotics are routinely used to treat AAD in clinical practice; however, the effectiveness and mechanisms by which probiotics alleviate symptoms remain poorly understood. We previously isolated a non-toxic Bacteroides fragilis strain ZY-312, which has been verified to be beneficial in certain infection disorders. However, the precise role of this commensal bacterium in AAD is unknown. In this study, we successfully established an AAD rat model by exposing rats to appropriate antibiotics. These rats developed diarrhea symptoms and showed alterations in their intestinal microbiota, including overgrowth of some pathogenic bacteria. In addition, gastrointestinal barrier defects, indicated by compromised aquaporin expression, aberrant tight junction proteins, and decreased abundance of mucus-filled goblet cells, were also detected in ADD rats compared with control animals. Of note, oral treatment with B. fragilis strain ZY-312 ameliorated AAD-related diarrhea symptoms by increasing the abundance of specific commensal microbiota. Interestingly, we demonstrated that these changes were coincident with the restoration of intestinal barrier function and enterocyte regeneration in AAD rats. In summary, we identified a potential probiotic therapeutic strategy for AAD and identified the vital roles of B. fragilis strain ZY-312 in modulating the colonic bacterial community and participating in microbiota-mediated epithelial cell proliferation and differentiation.